Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06316843 · ClinicalTrials.gov registry record · Phase 2
Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2
A Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19, sponsored by Bateman Horne Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT06316843 is a Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19 that has completed, run by Bateman Horne Center. The registered enrollment target is 59 participants, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06316843, a Phase 2 study of Long COVID and PASC Post Acute Sequelae of COVID 19, has completed, sponsored by Bateman Horne Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valacyclovir celecoxib dose 1
- DRUG Valacyclovir celecoxib dose 2
Study Locations (1)
Utah
- Bateman Horne Center - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2023-10-15 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06316843
The ClinicalTrials.gov registry entry for NCT06316843 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,187-participant average among 50 other Long COVID trials with a reported enrollment target (97% lower). The listed sponsor is Bateman Horne Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Long COVID appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06316843 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06316843 about?
NCT06316843 is a clinical study titled "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2". To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.
What is the current status of trial NCT06316843?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2023-10-15. Estimated completion is 2024-10-31.
What conditions does trial NCT06316843 study?
This clinical trial studies the following conditions: Long COVID, PASC Post Acute Sequelae of COVID 19.
What interventions are being tested in trial NCT06316843?
The interventions under investigation include: Placebo (DRUG), Valacyclovir celecoxib dose 1 (DRUG), Valacyclovir celecoxib dose 2 (DRUG).
Who is sponsoring clinical trial NCT06316843?
This trial is sponsored by Bateman Horne Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06316843 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NE3107 in Adults With Neurological Symptoms of Long COVID
RECRUITING · Phase 2
-
Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)
RECRUITING · Phase 2
-
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation
RECRUITING · Phase 2
-
AT1001 for the Treatment of Long COVID
RECRUITING · Phase 2
-
LIFT: Life Improvement Trial
RECRUITING · Phase 2
-
A Study to Examine Anktiva for the Treatment of COVID-19.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.